Related references
Note: Only part of the references are listed.Prediction of human pharmacokinetics using physiologically based modeling: A retrospective analysis of 26 clinically tested drugs
Stefan S. De Buck et al.
DRUG METABOLISM AND DISPOSITION (2007)
Physiologically based pharmacokinetic modelling 2: Predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions
Trudy Rodgers et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2006)
A novel strategy for physiologically based predictions of human pharmacokinetics
HM Jones et al.
CLINICAL PHARMACOKINETICS (2006)
Exploratory analysis for the evaluation of lopinavir/ritonavir-versus efavirenz-based HAART regimens in antiretroviral-naive HIV-positive patients: results from the Italian MASTER Cohort
C Torti et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2005)
Tissue distribution of basic drugs:: Accounting for enantiomeric, compound and regional differences amongst β-blocking drugs in rat
T Rodgers et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2005)
Physiologically based pharmacokinetic modeling 1: Predicting the tissue distribution of moderate-to-strong bases
T Rodgers et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2005)
Prediction of human drug clearance from in vitro and preclinical data using physiologically based and empirical approaches
K Ito et al.
PHARMACEUTICAL RESEARCH (2005)
Comparison of the use of liver models for predicting drug clearance using in vitro kinetic data from hepatic microsomes and isolated hepatocytes
K Ito et al.
PHARMACEUTICAL RESEARCH (2004)
Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection
GK Robbins et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure
A Antinori et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2002)
Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047
CJ Fichtenbaum et al.
AIDS (2002)
Predicting the impact of physiological and biochemical processes on oral drug bioavailability
B Agoram et al.
ADVANCED DRUG DELIVERY REVIEWS (2001)
Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors
PF Smith et al.
CLINICAL PHARMACOKINETICS (2001)
Adverse effects of antiretroviral therapy
A Carr et al.
LANCET (2000)
Share Paper
